zytiga

FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC

FDA · prostate cancer · 6 min

The FDA approved capivasertib plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The move creates a new catalyst for AstraZeneca’s Truqap and adds a biomarker-defined prostate cancer use to track.